NCT05210530View on ClinicalTrials.gov

An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

January 24, 2022

Primary Completion Date

January 19, 2023

Study Completion Date

January 19, 2023

Conditions
Diabetes MellitusDiabetes Mellitus, Type 1Glucose Metabolism DisordersMetabolic DiseaseEndocrine System DiseasesAutoimmune DiseasesImmune System Diseases
Interventions
COMBINATION_PRODUCT

VCTX210A unit

CRISPR-Cas9 genetically modified PEC210A cells loaded into a delivery device

Trial Locations (3)

Unknown

University of Alberta, Edmonton

University of British Columbia, Vancouver

LMC Manna, Toronto

Sponsors

Collaborators (1)

ViaCyte
All Listed Sponsors
collaborator

ViaCyte

INDUSTRY

lead

CRISPR Therapeutics AG

INDUSTRY